Hey, welcome to the first issue of Skim Insights.
This newsletter exists because the most important stories happening right now sit at the intersection of science, biotech, and money. That's what I'm here for. Every issue, I take one big story and give you my honest take on what it actually means.
🔬The Big Story
Anthropic Just Added a Pharma CEO to Its Board. This Isn't a Coincidence.
Most people know Anthropic as the AI safety company behind Claude (“the chatbot that competes with ChatGPT”). Most people, however, don't know that over the last six months, Anthropic has been quietly making big moves for the biotech industry. And the moves they've made tell a very clear biotech story.
Here's the pattern 👇
October 2025 — Claude for Life Sciences launches. Anthropic released a version of Claude built specifically for pharmaceutical researchers. It integrates with tools like PubMed and Benchling, and is already being used by Sanofi, AbbVie, and Novo Nordisk. This was a deliberate step into a new market (the Biotech market!).
April 2026 — Anthropic acquires Coefficient Bio for $400 million. Coefficient Bio had fewer than 10 employees and no public product. So why $400 million? Because their founders built drug discovery AI at Genentech, which is one of the most respected names in biotech. Anthropic didn't buy a company. They bought a team and a capability.
April 2026 — Novartis CEO Vas Narasimhan joins Anthropic's board. Vas has overseen 35+ drug approvals at Novartis. He's one of the most respected executives in global pharma. And he didn't join just any advisory committee or a partnership panel; he joined the board of one of the top AI companies right now.
Here's why: Anthropic's board isn't a typical corporate board. It's controlled by a Long-Term Benefit Trust, designed to keep the company accountable to its mission of safe and beneficial AI. Putting a pharma CEO on the board means Anthropic is treating drug development as a main part of who they are.
My Take
Three “big” moves in six months. A purposeful life sciences product. A $400M acqui-hire. A pharma CEO on the board.
This isn't a company dipping its hands in biotech. This is a very deliberate, sequenced strategy.
What I find most fascinating is the angle Anthropic is taking. They're not trying to discover drugs, but they're placing Claude as the intelligence layer that sits on top of the entire pharma R&D process. If everything follows suit, every major drug company in the world becomes a potential customer.
Wait, hold on. Then does this make Anthropic a tech company that helps pharma, or a pharma company that happens to use AI? Because the answer to this changes everything about how you value them.
I don't think we'll have clarity on this question for another two or three years. But the direction is unmistakable.
🗓️ Upcoming Deadlines
BIO International Convention 2026
The BIO International Convention is the world's leading collaboration platform for biotechnology and pharmaceutical industries, bringing together around 20,000 participants including investors, startup founders, pharma executives, and researchers. Register Now.
When: June 22–25, 2026
Location: San Diego, CA
TechCrunch Startup Battlefield
Startup Battlefield 200 applications open: a chance for VC access, TechCrunch coverage, and $100K.
Nominate yourself, a fellow founder, or a portfolio company by May 27.
Apply: Application Link
QUICK HITS
Other stories worth knowing about this week:
Gilead pays $3.15B for Tubulis — Another massive acquisition in the ADC (antibody-drug conjugate) space. ADCs are the hottest drug modality in biopharma right now. More on this in a future issue.
FDA Commissioner shares new policy requests with Congress — Regulatory shifts are coming that could affect how fast drugs get approved. Worth watching closely if you're tracking biotech investments.
STARTUP SPOTLIGHT
One startup worth knowing about this week.
Kailera Therapeutics Founded just in 2023, Kailera raised a $600M Series B by October 2025 (among the largest in biotech history!). Their strategy is to use AI and computational chemistry to develop next-gen weight-loss drugs that target multiple metabolic pathways simultaneously, claiming these therapies will be superior to existing medications like Ozempic.
The reason this is worth watching: they went from stealth to $600M in two years. This either means the science is genuinely breakthrough, or investors are incredibly hungry for the next GLP-1 that they're getting ahead of the data. Probably some of both.
💼 HOT BIOTECH & HEALTH JOBS THIS WEEK
Xaira Therapeutics — AI Drug Discovery | $1B+ founding round Role: Computational Biologist Location: San Francisco, CA Why it's hot: One of the most well-funded AI biotech startups right now, co-incubated by ARCH Venture Partners and Foresite Labs. Ground floor of something potentially very big.
Recursion Pharmaceuticals — AI Drug Discovery Platform Role: Machine Learning Engineer Location: Salt Lake City / Remote Why it's hot: Recursion operates BioHive-2, the fastest supercomputer in biopharma, and recently acquired rival Exscientia, giving it 10 drugs in preclinical and clinical development.
Formation Bio — AI Clinical Trials | $600M+ raised Role: Clinical Operations Associate Location: New York, NY Why it's hot: The company behind next week's main story. Already flipped drugs to Sanofi and Eli Lilly. Fast-moving and well-backed.
📖 WORD OF THE WEEK
Acqui-hire — When a company buys a startup primarily for its talent, not its product. Anthropic's $400M Coefficient Bio deal is a textbook example. The technology is important, but what they really paid for were the people who built it.
That's Issue 01. If this was useful, forward it to one person who'd find it interesting!
See you next week.